Athersys Secures Multiple Grants To Advance Key Therapeutic Programs In Regenerative Medicine And Obesity
CLEVELAND, Ohio, Nov. 4, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem ® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation. MultiStem is currently being developed for the treatment of AMI, Graft vs. Host Disease (GvHD) following bone marrow transplant, inflammatory bowel disease, and stroke. Additionally, one of the three awarded grants was secured to advance Athersys' pharmaceutical development program in obesity. Athersys is developing compounds that selectively stimulate the 5HT2c serotonin receptor in the brain, which is known to play an important role in regulating appetite. The Therapeutic Discovery Project grants totaled more than $730,000 in aggregate.
Athersys also announced today that it has secured a $140,000 grant from the Michael J. Fox Foundation for Parkinson's Research to advance research and development of its novel MultiStem product platform as a potential treatment for Parkinson's disease. The research funded by the grant is intended to confirm and extend previous observations regarding the efficacy of MultiStem in rodent models of Parkinson's disease, with the goal of accelerating the potential clinical application of these cells for patients who suffer from the disease.
"We are proud of the innovative work we have been conducting in these areas of true unmet medical need," said Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer of Athersys. "These grants not only underscore the promise and potential of our MultiStem platform and our obesity program, but help Athersys advance our research and clinical development activities across several key disease areas and accelerate our ongoing efforts to develop novel, safe and effective treatments for patients suffering from these conditions. We look forward to continuing to work with our development partners and to forging research relationships with visionary foundations like the Michael J. Fox Foundation for Parkinson's Research to help us reach this goal."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV